Why Barclays PLC, AstraZeneca plc & DS Smith plc Are Trading Far Too Cheaply!

Royston Wild explains why value seekers should check out Barclays PLC (LON: BARC), AstraZeneca plc (LON: AZN) and DS Smith plc (LON: SMDS).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am taking a look at the investment prospects of three blue-chip bargains.

The remedy for poor returns

Thanks to its revamped R&D strategy, I believe that pills provider AstraZeneca (LSE: AZN) is a great long-term stock bet for bargain hunters. The London business is doubling-down on its efforts in three hot growth areas, namely oncology; cardiovascular and metabolic diseases; and respiratory, inflammation and autoimmunity.

And the company is looking for between eight and 10 regulatory approvals for its drugs by the end of 2016, the company having already chalked up three so far this year.

While it is true patent lapses on key products are set to remain a headache — earnings dips of 1% and 5% are pencilled in for 2015 and 2016 respectively — I believe AstraZeneca’s rejuvenated pipeline, allied with surging healthcare demand the world over, should power earnings further out. And consequently a prospective P/E rating of 16.1 times represents a decent level to get in at.

Indeed, AstraZeneca’s improving revenues outlook is expected to offer up market-busting dividends despite the colossal sums required for R&D. A predicted 280-US-cent-per-share reward through to the end of 2016 creates an excellent 4.1% yield.

Box up a bargain

I am convinced that boxbuilder DS Smith (LSE: SMDS) is also a top stock for those seeking great growth at brilliant prices, even if this week’s financials left something to be desired. The business advised that the impact of adverse currency movements, combined with restructuring at its European operations, drove pre-tax profit 26% lower during May-October, to £91m.

Still, DS Smith advised that volumes continue to grow ahead of the wider market, and its focus on creating cutting-edge packaging technologies — allied with ambitious expansion on the continent — providing plenty of upside for the coming years in my opinion. The manufacturer also announced the purchase of Turkish corrugated packaging specialist Milas Ambalaj yesterday.

DS Smith is expected to clock up earnings growth of 7% and 12% for the years concluding April 2016 and 2017 correspondingly, resulting in very reasonable P/E ratios of 15.9 times and 14.2 times. And predicted dividends of 12.3p per share for 2016 and 13.3p for 2017 create handy yields of 3% and 3% accordingly.

A financial favourite

Life has the potential to get a little more bumpy over at Barclays (LSE: BARC) following the installation of Jes Staley as chief executive during the autumn. The subsequent resurrection of the firm’s Investment Bank is a highly-divisive move, significantly increasing the bank’s risk profile that previous company head Antony Jenkins had made a point of significantly reducing.

And Barclays’ changing focus attracted the headlines again this week after Reuters reported that Staley had attempted to hire Blythe Masters — the inventor of controversial credit default swaps — to oversee the division.

While the aims of the new administration creates some uncertainty going forward, I believe there is still plenty for investors to get excited about — the improving UK economy should continue to lend Barclays’ High Street operations a hand, while the firm’s Barclaycard division and African assets provide plenty of long-term opportunities.

Barclays is expected to enjoy earnings upticks to the tune of 28% and 19% in 2015 and 2016 respectively, producing ultra-low P/E ratios of 10.2 times and 8.3 times. And an estimated dividend of 6.5p per share for 2015, yielding 2.9%, is expected to leap to 8.2p in 2016, driving the yield to 3.7%.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild owns shares of DS Smith. The Motley Fool UK has recommended AstraZeneca, Barclays, and DS Smith. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »